Sign In | Join Free | My vivirlatino.com
vivirlatino.com
Hongkong Kangdisen Medical Co., Limited
Hongkong Kangdisen Medical Co., Limited Serve People's Health
Home > Epidermal Growth Factor >

Ipamorelin Acetate Peptide Human Growth Factor 170851-70-4 Penta Peptide Hormone

Hongkong Kangdisen Medical Co., Limited
Trust Seal
Verified Supplier
Credit Check
Supplier Assessment

Ipamorelin Acetate Peptide Human Growth Factor 170851-70-4 Penta Peptide Hormone

Brand Name : KANGDISEN
Model Number : 2 mg/vial
Certification : GMP
Place of Origin : China
MOQ : negotiatable
Price : negotiatable
Payment Terms : MoneyGram, T/T, Bitcoin
Supply Ability : 100,000 vials each month
Delivery Time : 3 days
Packaging Details : 10 vials/kit
Sequence : Aib-His-D-2-Nal-D-Phe-Lys-NH2
Vacuum : Vacuum
Appearance : lyophilized powder
Purity : more than 98%
Synonyms : Ipamorelin Acetate, IPAM, NNC-26-0161 , Ipamorelin Acetate peptide 170851-70-4 penta-peptide hormone
CAS : 170851-70-4
Contact Now


Ipamorelin Acetate Peptide Human Growth Factor 170851-70-4 Penta Peptide Hormone​


Ipamorelin

Ipamorelin is a penta-peptide hormone (Aib-His-D-2-Nal-D-Phe-Lys-NH2), a growth hormone secretagogue and a small molecule ghrelin mimetic developed by Novo Nordisk. Ipamorelin belongs to the most recent generation of GHRPs and causes significant release of growth hormone. Similar to GHPR-6 and GHPR-2, it suppresses somatostatin and increases the stimulation and release of Growth Hormone (GH) from the anterior pituitary. Currently, there are few clinical trials involving Ipamorelin, which were first being studied in the 90s. Somatotropes are the cells that are responsible for producing and releaseing GH.



Ipamorelin Peptide

Ipamorelin

Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular formula: C38H49N9O5
Molar Mass: 711.85296
CAS number: 170851-70-4
PubChem: CID 20754357
Synonyms: Ipamorelin Acetate, IPAM, NNC-26-0161




The Ipamorelin Growth Hormone Releasing Peptide Comparison

Ipamorelin is a 3rd generation GHRP behind GHRP-6 and GHRP-2. Ipamorelin has very similar characteristics of GHRP-2: does not have ghrelin's lipogenic properties and does not promote hunger. Ipamorelin acts synergistically when applied during a Growth Hormone Releasing Hormone (GHRH) pulse or when it is administered along with a GHRH or an analog such as Sermorelin or Modified GRF 1-29 (growth releasing factor, aminos 1-29). The synergy comes both due to the suppression of somatostatin and the fact that ipamorelin increases GH release per-somatotrope, while GHPR increases the number of somatotropes releasing GH.

On the other hand, Ipamorelin is similar to GHRP-6 because they both release GH at a very similar strength minus the side effects that of GHRP-6. Both GHRP-6 and GHRP-2 cause a release and an increase in cortisol and prolactin levels, however Ipamorelin only selectively releases GH at any dose. Ipamorelin shares similar functionality to Hexarelin and compared to other peptides, it is a much more stable form of ghrelin and has longer half-life periods of at least two hours long and causes secondary effect by making neurons to become excited.




Studies Related to Ipamorelin

Ipamorelin has been shown to be both highly potent and very selective in vivo and vitro situations, and has also demonstrated good safety and tolerability in human clinical studies. Research has shown that Ipamorelin is growth hormone specific which means that the pituitary hormones such as cortisol are unaffected. In one study, it was found that young female adult rats had increased bone mass due to 12 weeks of treatment with ipamorelin. This peptide compared to other Growth Hormone Releasing peptides ensures the benefits without having to deal with possible negative side effects.


Ipamorelin is a growth hormone releasing peptide (GHRP) similar to GHRP2 and GHRP6 that was developed by Novo Nordisk. It is a pentapeptide composed of 5 amino acids that causes a significant release of growth hormone from the anterior pituitary gland, and has the dual action of also suppressing somatostatin, a peptide hormone that inhibits the release of growth hormone. The benefits of using Ipamorelin are increased fat loss, maintenance of lean muscle tissue, rejuvenation and strengthening of joints, connective tissue and bone mass, as well as other anti aging benefits associated with GH treatment such as improved skin tone and hair quality. It can also be used to increase low GH levels when natural GH secretion has been inhibited by long-term abuse of synthetic GH.


Ipamorelin is the first growth hormone releasing peptide to be developed that has the unique selective property of stimulating only the release of GH without also significantly increasing cortisol, or prolactin, even at doses more than 200 times higher than an average effective dose. It has no effect on testosterone, LH, or FSH levels and no post cycle therapy is needed after using it. It releases GH with a strength comparable to GHRP6, but without the associated side effects. This makes ipamorelin a wonderful candidate for research and probably the safest peptide to use. In a clinical study conducted on 48 adult men, even mega doses of 600mcg/kg were demonstrated to be safe and well tolerated.

The recommended effective dose is 1mcg/kg of bodyweight (100mcg for a man weighing 100kg). It elevates GH levels for about 3.5 hours after subcutaneous injection, and best results are obtained when using 3 or 4 doses per day. For those who wish to use it only once a day for anti-aging purposes, the best time to use it is right before bed, preferably with a GHRH. Ipamorelin has a synergistic effect when administered during a natural GH pulse and optimal times for use are at night right before bed, pre workout or immediately post workout, and first thing in the morning.

The saturation dose for most GHRPs (GHRP2, GHRP6, Hexarelin) is generally defined as 1mcg/kg, meaning that any dose over that will have much less of an effect the higher you go over it. Ipamorelin also has a diminishing effect over 1mcg/kg but where Ipamorelin is unique, unlike the other GHRPs, is that it can be taken in significantly higher doses resulting in a mega-release of GH up to the entire amount present in the pituitary gland.

For an even greater synergistic effect ipamorelin should be taken together with a GHRH (growth hormone releasing hormone) like CJC1295 w/o DAC. The synergy is due to ipamorelin’s suppression of somatostatin, and that it increases the amount of GH release per somatotrope (cells in the pituitary that release growth hormone), while the GHRH increases the number of somatotropes that will release GH. What this means is that if ipamorelin on it’s own causes 4 ‘units’ to be released, and the GHRH causes 3 to be released, the synergistic effect of using them together could result in 15 being released.

Ipamorelin is usually supplied in 2mg vials containing the freeze-dried peptide, which needs to be reconstituted with bacteriostatic water. Once the peptide is reconstituted, it should be used within 8 weeks and should be stored in the fridge between 2°C - 8 °C. If the ipamorelin does not dissolve minutes do not shake the solution as this can damage the peptide. Gently swirl the mixture or leave it a while longer and it should dissolve within a few minutes.








































Product Tags:

egf growth factor

      

recombinant growth factors

      
China Customized Inflatable Bumper Ball Game Bubble Adult Grass CE supplier

Ipamorelin Acetate Peptide Human Growth Factor 170851-70-4 Penta Peptide Hormone Images

Inquiry Cart 0
Send your message to this supplier
 
From:
Enter your email please.
To: Hongkong Kangdisen Medical Co., Limited
Subject:
Message:
Characters Remaining: (0/3000)
 
Inquiry Cart 0